论文部分内容阅读
经导管动脉内栓塞术(TAE)治疗肝细胞肝癌(HCC),是目前应用广泛的姑息疗法,经导管碘油加抗癌药物混合栓塞(TOCE)的应用,也取得了令人满意的效果,但是HCC合并门脉癌栓被认为是TAE的禁忌证,因为它将直接导致肝
Transcatheter arterial embolization (TAE) for the treatment of hepatocellular carcinoma (HCC) is a widely used palliative therapy. The application of transcatheter lipiodol plus anticancer drug mixed embolism (TOCE) has also achieved satisfactory results. However, HCC combined with portal vein tumor thrombi is considered a TAE contraindication because it will directly lead to liver